Information Provided By:
Fly News Breaks for July 24, 2019
EW
Jul 24, 2019 | 09:11 EDT
Raymond James analyst Jayson Bedford raised his price target for Edwards Lifesciences to $232 from $200 on increased confidence given a sharp acceleration in TAVR growth and an earlier than expected approval for Low Risk. The analyst reiterates an Outperform rating on the shares.